| Date | Filer | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| May 12, 2006 | VP - Clin. Dev. & Med. Affairs | Form 4 | Open market or private purchase of non-derivative or derivative security | 300 | $3.75 | 2,300 | |
| March 15, 2006 | VP - Regulatory Affairs | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 2,369 | -- | 2,369 | |
| January 14, 2011 | Chief Medical Officer | Form 4 | Open market or private purchase of non-derivative or derivative security | 2,499 | -- | 2,500 | |
| December 6, 2011 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 2,500 | $2.31 | 2,500 | |
| September 30, 2022 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 2,667 | -- | 2,667 | |
| August 10, 2010 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 3,000 | $3.35 | 3,000 | |
| January 14, 2011 | CFO | Form 4 | Open market or private purchase of non-derivative or derivative security | 3,333 | -- | 3,333 | |
| January 14, 2011 | Controller & CAO | Form 4 | Open market or private purchase of non-derivative or derivative security | 3,333 | -- | 3,333 | |
| November 16, 2005 | EVP, CFO | Form 4 | Open market or private purchase of non-derivative or derivative security | 3,700 | $0.29 | 3,700 | |
| May 12, 2006 | VP - Clin. Dev. & Med. Affairs | Form 4 | Open market or private purchase of non-derivative or derivative security | 1,700 | $3.75 | 4,000 | |
| March 17, 2023 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 2,000 | -- | 4,667 | |
| January 14, 2011 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 4,999 | -- | 5,000 | |
| February 2, 2016 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 5,000 | $1.33 | 5,000 | |
| February 2, 2016 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 5,000 | $1.33 | 5,000 | |
| June 20, 2014 | Chief Scientific Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 5,000 | $3.50 | 5,000 | |
| June 17, 2008 | VP & Chief Medical Officer | Form 3 | Initial Statement of Beneficial Ownership of Securities | -- | -- | 5,000 | |
| May 26, 2011 | Controller & CAO | Form 4 | Open market or private purchase of non-derivative or derivative security | 1,727 | $0.12 | 5,060 | |
| May 17, 2021 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 5,000 | $1.07 | 5,357 | |
| June 13, 2022 | Chief Accounting Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 1,750 | -- | 5,833 | |
| July 7, 2017 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 6,500 | $1.90 | 6,500 | |
| March 15, 2006 | VP - Operations | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 4,534 | -- | 6,534 | |
| May 15, 2018 | Director | Form 4 | Other acquisition or disposition (describe transaction) | 6,250 | $2.24 | 6,607 | |
| May 26, 2011 | CFO | Form 4 | Open market or private purchase of non-derivative or derivative security | 3,454 | $0.12 | 6,787 | |
| December 6, 2011 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 5,000 | $2.31 | 7,000 | |
| March 15, 2006 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 3,676 | -- | 7,010 |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.
